Clinical and neuroimaging study on preclinical Alzheimer's disease. - AMED-Preclinical

Osaka City University0 sites40 target enrollmentDecember 1, 2015

Conditionsmild cognitive impairment, preclinical Alzheimer disease

Overview

Phase: 未知
Intervention: Not specified
Conditions: mild cognitive impairment, preclinical Alzheimer disease
Sponsor: Osaka City University
Enrollment: 40
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

December 1, 2015

End Date

March 31, 2020

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Osaka City University

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•1\. Parkinson' disease, Lewy body dementia, frontotemporal dementia, Huntington's disease, progressive supranuclear palsy or other neurodegenerative diseases other than AD. Multiple cerebral infarction, normal pressure hydrocephalus, brain tumor, epilepsy, subdural hematoma, multiple sclerosis, head trauma with sequelae will also be excluded. 2\. Signs of brain infection, focal brain lesions (eg infarction) that may affect cognitive function. Individuals with subcortical small infarction or diffuse white matter lesions can be included except for those in specific lesions affecting cognition. Cortical infarcts are normally excluded. 3\. Presence of pacemaker, arterial clip, artificial valves, artificial cochlea, and other magnetic/electroconductive metals in the body that may affect MRI scan. 4\. Major depression or bipolar disorder within past 1 year, past history of schizophrenia, defined by DSM\-IV. 5\. Addiction to alcohol or other drugs within past 2 years. 6\. Past history of psychiatric symptoms, agitation or abnormal behaviors that affect protocol adherence within past 3 months. 7\. Presence of fatal or unstable diseases. 8\. Vitamin B12 or folate deficiency, syphilis, thyroid function abnormality. 9\. Admission to care home or hospitals. 10\. Administration of specific drugs (defined in the procedure manual) including psychoactive drugs and warfarin. 11\. Administration of any drugs in clinical trial within 1 month prior to screening. 12\. Participation in clinical studies or clinical trials other than AMED preclinical. 13\. Probable participation in clinical trials for Alzheimer's disease drugs during the study duration of 3 years. 14\. Decision of exclusion otherwise judged by site study physician or clinical core.